Biotech Sued for Off-Label Marketing
Amgen's (NASDAQ: AMGN) was approved for specific uses by the FDA, but the company marketed its drug for other things, too.

This Article Originally was Published here:

Noted biotech company Amgen (NASDAQ: AMGN) has run into trouble with federal prosecutors, who claim the company violated FDA restrictions to market the anemia drug Aranesp for unapproved purposes.

The New York Times reports:

Amgen was “pursuing profits at the risk of patient safety,” Marshall L. Miller, acting United States attorney in Brooklyn, said in a telephone news briefing on Tuesday.

Amgen pleaded guilty to the illegal marketing of Aranesp and agreed to pay $762 million in penalties and settlements.

$612 million will go toward settling civil litigation. Another $136 million will go toward criminal fines, and there will be a forfeiture of $14 million.

Judge Sterling Johnson Jr., who is presiding over the case, agreed to Amgen’s offer—a move that opened up the possibility for further whistle-blower suits and more expansive settlements.

The specific problem appears to be that Amgen marketed Aranesp as a drug for use in treating anemia in cancer patients not under chemotherapy. Aranesp had only been approved for patients already undergoing chemotherapy. As a result, risk for death increased for patients not under chemotherapy—and ironically, this finding emerged from a study sponsored by Amgen.

Further, federal prosecutors alleged that Amgen suggested the drug be used in larger, less frequent doses in order to compete with Johnson and Johnson’s (NYSE: JNJ) Procrit, a rival drug.

Amgen did try to obtain FDA approval for this large-dose system, but the FDA declined to approve it citing inadequate research. Nevertheless, Amgen persisted in promoting larger doses, citing the same studies the FDA had rejected.

Off-label marketing, the practice Amgen engaged in, has become a concern in recent years; the government has collected several billions in fines over such cases. Just back in July, GlaxoSmithKline (NYSE: GSK) coughed up $3 billion over similar charges.

An interesting twist to the affair emerges when one considers that Aranesp used to be the biotech's star product—it chalked up more than $4 billion in yearly sales. However, increasingly critical studies contributed to reducing sales since 2007. In the first nine months of 2012, worldwide sales amounted to just $1.55 billion.

On Tuesday, Amgen stock fell to $89.29, down 21 cents. It was down another 35 cents on Thursday morning to $88.14.


This Article Originally was Published here:

Biotech Sued for Off-Label Marketing originally appeared in Wealth Daily. Wealth Daily, a free daily newsletter, offers practical investment analysis and contrarian stock market advice.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here